10-Fold increase (2006-11) in the rate of healthy subjects with extendedspectrum beta-lactamase-producing Escherichia coli faecal carriage in a Parisian checkup centre, J Antimicrob Chemother, vol.68, issue.3, pp.562-570, 2013. ,
Faecal carriage of extended-spectrum ??-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology, Journal of Antimicrobial Chemotherapy, vol.18, issue.1, pp.1142-1151, 2008. ,
DOI : 10.1017/S0950268806005917
Rapid Dissemination and Diversity of CTX-M Extended-Spectrum ??-Lactamase Genes in Commensal Escherichia coli Isolates from Healthy Children from Low-Resource Settings in Latin America, Antimicrobial Agents and Chemotherapy, vol.51, issue.8, pp.2720-2725, 2007. ,
DOI : 10.1128/AAC.00026-07
High prevalence of CTX-M-15 and first report of CTX-M-3, CTX-M-22, CTX-M-28 and plasmid-mediated AmpC beta-lactamase producing Enterobacteriaceae causing urinary tract infections in Bosnia and Herzegovina in hospital and community settings, Journal of Infection and Chemotherapy, vol.21, issue.5 ,
DOI : 10.1016/j.jiac.2015.01.003
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-esbl producing klebsiella pneumoniae. Diagnostic microbiology and infectious disease, pp.41-47, 2004. ,
In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, pp.831-840, 2014. ,
Cefepime, Piperacillin-Tazobactam, and the Inoculum Effect in Tests with Extended-Spectrum beta -Lactamase-Producing Enterobacteriaceae, Antimicrobial Agents and Chemotherapy, vol.45, issue.12 ,
DOI : 10.1128/AAC.45.12.3548-3554.2001
The inoculum effect of antibiotics against CTX-Mextended-spectrum ?-lactamase-producing Escherichia coli, Annals of Clinical Microbiology and Antimicrobials, vol.13, p.45, 2014. ,
Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, pp.894-900, 2012. ,
A prospective study of ceftriaxone treatment in acute pyelonephritis caused by extended-spectrum beta-lactamaseproducing bacteria, Journal of the Medical Association of Thailand = Chotmaihet thangphaet, vol.91, issue.8, pp.1172-81, 2008. ,
Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum betalactamase-producing Escherichia coli. Diagnostic microbiology and infectious disease, pp.351-358, 2006. ,
Communityonset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, pp.40-48, 2010. ,
Carbapenem Therapy Is Associated With Improved Survival Compared With Piperacillin-Tazobactam for Patients With Extended-Spectrum beta-Lactamase Bacteremia. Clinical infectious diseases : an official publication of the, Infectious Diseases Society of America, vol.60, issue.9, pp.1319-1344, 2015. ,
Comparable outcomes for beta-lactam/beta-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae. Antimicrobial resistance and infection control beta-Lactam/betalactam inhibitor combinations for the treatment of bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, pp.14167-74, 2012. ,
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum ??-lactamases: a systematic review and meta-analysis, Journal of Antimicrobial Chemotherapy, vol.63, issue.2, pp.2793-803, 2012. ,
DOI : 10.1016/j.diagmicrobio.2008.11.004
The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials, The Journal of the Association of Physicians of India, vol.60, pp.28-30, 2012. ,
ABSTRACT, Antimicrobial Agents and Chemotherapy, vol.56, issue.3 ,
DOI : 10.1128/AAC.06233-11
Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates, Journal of Antimicrobial Chemotherapy, vol.58, issue.5, pp.1074-1081, 2006. ,
DOI : 10.1093/jac/dkl381
The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae, International Journal of Infectious Diseases, vol.17, issue.3, pp.159-63, 2013. ,
DOI : 10.1016/j.ijid.2012.09.010
Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniaein patients on maintenance hemodialysis, BMC Infectious Diseases, vol.39, issue.Suppl 5, pp.206-247, 2012. ,
DOI : 10.1086/420816
Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 ??-lactamases, Journal of Antimicrobial Chemotherapy, vol.43, issue.2 ,
DOI : 10.1086/503264
In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase. The Journal of infectious diseases, pp.1005-1011, 1989. ,
Role of Old Antibiotics in the Era of Antibiotic Resistance ,
Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli Archives of internal medicine Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urology annals, pp.1897-90226, 2008. ,
CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin, Journal of Antimicrobial Chemotherapy, vol.61, issue.2, pp.712-719, 2009. ,
DOI : 10.1093/jac/dkm464
Postoperative Meningitis and Epidural Abscess due to Extended-spectrum ^|^beta;-Lactamase-producing Klebsiella pneumoniae: A Case Report and a Review of the Literature, Internal Medicine, vol.51, issue.18, pp.2645-2653, 2012. ,
DOI : 10.2169/internalmedicine.51.8068
Extended spectrum beta lactamase peritonitis: Time for innovation? Indian journal of nephrology, pp.374-380, 2012. ,
Bacteremia due to extended-spectrum beta-lactamaseproducing Enterobacteriaceae other than Escherichia coli and Klebsiella The efficacy of noncarbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli Clinical outcome of extendedspectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, pp.496-5022848, 2006. ,
Epidemiology of third-generation cephalosporin-resistant community-acquired Enterobacteria isolated from elderly patients, M??decine et Maladies Infectieuses, vol.44, issue.2, pp.57-62, 2014. ,
DOI : 10.1016/j.medmal.2013.11.008
Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli, Journal of Infection, vol.55, issue.3, pp.254-263, 2007. ,
DOI : 10.1016/j.jinf.2007.04.007
Extended-Spectrum ??-Lactamases: a Clinical Update, Clinical Microbiology Reviews, vol.18, issue.4 ,
DOI : 10.1128/CMR.18.4.657-686.2005
Diangnostic et antibiothérapie des infections urinaires bactériennes communautaires de l'adulte ,
Piperacillin???tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum ??-lactamase-producing Escherichia coli and Klebsiella pneumoniae, Journal of Infection, vol.64, issue.5, pp.533-537, 2012. ,
DOI : 10.1016/j.jinf.2012.01.008
Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting, Journal of Antimicrobial Chemotherapy, vol.40, issue.5, pp.1219-1244, 2015. ,
DOI : 10.1097/CCM.0b013e3182416ecf
The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria, Infection, vol.11, issue.6, pp.555-61, 2011. ,
DOI : 10.1016/S1473-3099(11)70005-6
Risk Factors and Prognosis of Nosocomial Bloodstream Infections Caused by Extended-Spectrum-??-Lactamase-Producing Escherichia coli, Journal of Clinical Microbiology, vol.48, issue.5, pp.1726-1757, 2010. ,
DOI : 10.1128/JCM.02353-09
Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, pp.1041-1048, 2008. ,
Extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, pp.1162-71, 2001. ,
Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, pp.653-662, 2008. ,